bezafibrate has been researched along with benzoxazoles in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Endo, H; Kagaya, Y; Kanazawa, M; Kondo, M; Miura, M; Nakamura, A; Saito, H; Sato, K | 1 |
1 trial(s) available for bezafibrate and benzoxazoles
| Article | Year |
|---|---|
Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study.
Topics: Adult; Aged; Apolipoprotein A-I; Benzoxazoles; Bezafibrate; Butyrates; Cholesterol, HDL; Cross-Over Studies; Female; Humans; Hypertriglyceridemia; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Treatment Outcome; Triglycerides | 2023 |
1 other study(ies) available for bezafibrate and benzoxazoles
| Article | Year |
|---|---|
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |